DC Marijuana Sales Appropriations Rider: History, Impact, and Status
The DC marijuana sales appropriations rider is a provision in annual federal spending bills that bars the District of Columbia from using its funds to set up a regulated, taxed cannabis retail market. Introduced in 2014 as the Harris rider, it has let DC residents possess and grow limited amounts of cannabis under Initiative 71 while blocking legal sales. This hub explains the rider's origin, how it operates, why the district's unusual legal status makes it possible, how the unregulated gifting market emerged, and the latest congressional action, including Senate appropriators' recent push to keep the restriction in place.

Executive Summary
The "Harris Rider" has blocked the District of Columbia from regulating and taxing recreational marijuana sales every fiscal year since 2015, and a Senate appropriations panel is again moving to keep it in place. The rider is a one-sentence provision in the annual Financial Services and General Government (FSGG) appropriations bill. It bars the District from spending any funds, local or federal, to "enact any law, rule, or regulation to legalize or reduce penalties associated with the possession, use, or distribution" of any Schedule I substance, including marijuana.
The result is a legal paradox. Voters in the District approved Initiative 71 in November 2014 with roughly 70 percent support, and possession and home cultivation have been legal since February 26, 2015. But the District cannot license dispensaries or collect sales tax on recreational cannabis. A gray market of "gifting" shops, where a product is "given away" with the purchase of a T-shirt or sticker, fills the vacuum, while the District's licensed medical program operates separately under the 2010 Legalization of Marijuana for Medical Treatment Initiative Amendment Act.
According to Marijuana Moment's reporting on November 19, 2026, a Senate panel wants to continue the block on DC sales while also urging federal agencies to keep drug testing for cannabis in place as the federal government works through the rescheduling of marijuana from Schedule I to Schedule III. That pairing shows how the DC fight is now entangled with the wider federal regulatory shift, including the rulemaking track at the DEA and the Department of Health and Human Services (HHS).
This hub explains the rider's history, legal mechanics, the players on each side, the market consequences, and the calendar that determines whether the rider survives another cycle.
Why This Matters
The rider denies roughly 700,000 District residents a regulated adult-use market, forfeits tens of millions of dollars in annual tax revenue, and leaves consumers dependent on unregulated sellers. Few other cannabis policy questions combine home rule, congressional power, and a measurable market failure so directly.
Home rule and democratic legitimacy
The District has no voting representation in Congress, so a rider written by members who do not answer to DC voters overrides a ballot measure those voters passed. Advocates, including the DC Cannabis Trade Association and Mayor Muriel Bowser's allies on the Council, have argued for a decade that the rider is the clearest modern example of Congress using its plenary authority under Article I, Section 8, Clause 17 of the Constitution (the District Clause) to override local policy on a single, narrow issue.
Public safety and consumer protection
Because no licensing regime exists, nobody tests the products sold in gifting shops for potency, pesticides, heavy metals, or mold. Operators who would otherwise be licensed have no mechanism to demonstrate compliance, and the District cannot impose packaging, child-resistance, or advertising rules on the recreational market. Regulators in other jurisdictions treat these controls as the core public-health benefit of legalization.
Fiscal stakes
Neighboring and comparable markets show what is at stake. Maryland launched adult-use sales on July 1, 2023, and Virginia, which legalized possession but still lacks a retail market, has drawn the same criticism for creating an unregulated supply chain. DC advocates cite revenue projections in the tens of millions of dollars annually from a taxed market; those figures vary by study and depend on the tax rate and the number of licenses, so operators should treat any single estimate with caution.
Federal entanglement
The latest news ties the DC rider to the federal rescheduling process. If marijuana moves to Schedule III under the Controlled Substances Act (21 U.S.C. § 812), the rider's own text, which targets "Schedule I" substances, raises a question that has not been tested: does a rider written around Schedule I still reach marijuana once it is no longer Schedule I? Appropriators have signaled they intend to keep the block regardless, and drafting language is where that fight will play out.
Background and History
The rider has survived every appropriations cycle for more than a decade, through Republican and Democratic control of Congress, because it is cheap to renew and politically difficult to strip. The timeline below traces how a local ballot measure became a recurring federal flashpoint.
1998: The first ballot measure is blocked
DC's cannabis fight with Congress predates Initiative 71 by sixteen years. In November 1998, District voters approved Initiative 59, a medical marijuana measure. Congress responded with the Barr Amendment, authored by then-Representative Bob Barr, which barred the District from counting or certifying the ballot results. Courts later allowed the results to be released, revealing the measure had passed with roughly 69 percent, but the Barr rider blocked implementation for years. It remained in place until Congress allowed it to lapse in the 2009 appropriations cycle.
2010: Medical program authorized
With the Barr language gone, the DC Council enacted the Legalization of Marijuana for Medical Treatment Initiative of 1999 Amendment Act of 2010. The program was deliberately restrictive: a small number of licensed cultivation centers and dispensaries, a limited qualifying-condition list, and strict patient registration. Dispensaries opened in 2013. This program is unaffected by the current rider, since the rider targets recreational legalization and penalty reduction rather than the previously authorized medical system.
2014: Decriminalization and Initiative 71
In 2014 the Council passed the Marijuana Possession Decriminalization Amendment Act, reducing possession of up to one ounce to a civil violation with a $25 fine. That November, voters approved Initiative 71, the Legalization of Possession of Minimal Amounts of Marijuana for Personal Use Initiative, by a margin of about seven to three. The measure allowed adults 21 and older to possess up to two ounces, grow up to six plants (three mature), and transfer up to one ounce without payment.
December 2014: The Harris Rider is born
Representative Andy Harris, a Maryland Republican and physician, attached language to the FY2015 "cromnibus" spending package that barred the District from using funds to implement any law reducing penalties for Schedule I drugs. Harris argued that the Council's actions violated that prohibition. The rider was signed into law as part of Public Law 113-235. Initiative 71 nonetheless took effect on February 26, 2015, after the Congressional review period, because the District's attorney general and Council argued that the initiative had been "enacted" before the rider passed, so the rider could not reach it.
2015: Dispute over enforcement
Harris and some House allies contended that the District's ongoing implementation violated the rider and might expose officials to Antideficiency Act penalties, which carry potential criminal liability for spending money in violation of appropriations law. The Government Accountability Office and the Department of Justice did not pursue enforcement against District officials, but the threat shaped how cautious the Council became about regulating commercial sales.
2016-2017: Tax-and-regulate bills stall
Councilmember David Grosso introduced the Marijuana Legalization and Regulation Act. The Council held hearings but could not advance a commercial framework because any such bill would hit the rider directly. Meanwhile, gifting businesses proliferated, and the District's attorney general and the Alcohol Beverage Regulation Administration issued warnings and enforcement actions against some operators.
2018-2021: Persistent attempts to strip the rider
In 2019 the House Appropriations Committee, under Democratic control, dropped the rider from its FSGG bill, and the House passed spending bills without it. Senate Republicans and, ultimately, the final negotiated packages restored it. The pattern repeated in the FY2021 and FY2022 cycles: the House stripped the language, and the Senate or conference process put it back. In 2022 the Biden White House's budget request similarly omitted the rider, but it nevertheless resurfaced in final enacted legislation.
2022-2025: Regional pressure builds
Maryland's 2022 ballot measure and the July 2023 launch of adult-use sales put a regulated market a few miles from the District border. Virginia's incomplete rollout, which legalized possession in 2021 without a retail framework, drew parallel criticism. Meanwhile, enforcement priorities within the District, including a 2022 federal prosecution posture that left gifting shops largely alone, created a de facto tolerated market.
2024-2026: Rescheduling enters the picture
The Biden administration's HHS recommendation in 2023 to move marijuana to Schedule III, followed by the DEA's proposed rule and the subsequent administrative law judge (ALJ) hearing process, introduced a new variable. The November 2026 Senate panel action, as reported by Marijuana Moment, shows appropriators holding the DC line while also addressing how federal agencies handle cannabis drug testing during a rescheduled regime. That drug-testing language reflects pressure from transportation and workplace-safety stakeholders who worry that rescheduling could be read to loosen testing requirements.
Key Players
The fight pits a handful of congressional appropriators and a small group of district officials and advocates against each other, with the White House and DEA acting as background variables.
Representative Andy Harris (R-MD)
The rider's namesake and chief defender. Harris, who practices as an anesthesiologist, has framed his opposition in terms of public health and Congress's constitutional authority over the District. He has repeatedly resisted attempts to strip the language and has been a consistent obstacle to any compromise that would let DC regulate sales.
Senate and House Appropriations Committees
The FSGG subcommittees in each chamber write the vehicle that carries the rider. The Senate panel's recent decision, reported by Marijuana Moment, to preserve the block shows that even when the House has moved to strip it, the Senate side of the process remains the more reliable guardian of the language.
District of Columbia Council and Mayor Muriel Bowser
The Council passed the original decriminalization bill and has repeatedly signaled support for a regulated market. Mayor Bowser has publicly criticized the rider and argued that Congress should respect local democratic choices. The Council cannot act on commercial sales without risking a collision with the rider.
Delegate Eleanor Holmes Norton
The District's nonvoting delegate to the House of Representatives has made rider repeal a core legislative priority, introducing standalone bills and lobbying appropriators each cycle. Her position is that DC residents have an equal right to determine their own cannabis policy.
Advocacy groups
The Marijuana Policy Project, the Drug Policy Alliance, and local groups such as the DC Cannabis Trade Association push for repeal or modification. Their arguments focus on home rule, equity, and consumer safety. The Initiative 71 campaign's leadership, including activist Adam Eidinger, remains active and has long argued for a regulated commercial system.
DEA and HHS
Though not parties to the rider fight, the Drug Enforcement Administration and the Department of Health and Human Services control the rescheduling track. The final form of any Schedule III rule, and how it interacts with federal appropriations language that references Schedule I, will shape the rider's legal reach.
Opposition and wary stakeholders
Prevention-oriented groups and some law enforcement organizations oppose lifting the rider, citing concerns about youth access and impaired driving. The Senate panel's drug-testing language reflects this coalition's influence, particularly on federal workforce and transportation testing policy.
Legal and Regulatory Framework
The rider works through appropriations law rather than a freestanding statute, which means it must be renewed annually and can be stripped by any single cycle's negotiations.
The rider text
Each year the FSGG bill, under the section governing the District of Columbia, includes a prohibition stating that none of the funds contained in the Act may be used to enact or carry out any law, rule, or regulation to legalize or reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act, or any tetrahydrocannabinol derivative. The language, first enacted in Public Law 113-235, has been carried forward in essentially identical form.
The Antideficiency Act
The enforcement mechanism that worries District officials is the Antideficiency Act, 31 U.S.C. § 1341, which prohibits federal and District officials from obligating funds in violation of appropriations. Violations can carry administrative discipline and, for knowing and willful violations, criminal penalties. No District official has been prosecuted under this theory, but the risk constrains the Council's willingness to pass commercial legislation.
The District Clause and home rule
Congress governs the District under Article I, Section 8, Clause 17 of the Constitution, and delegated limited local authority through the District of Columbia Home Rule Act of 1973. The Home Rule Act itself reserves to Congress the power to legislate on any DC matter, and its Section 603 restricts the District's expenditure authority to funds Congress has appropriated. Courts have consistently upheld Congress's authority to condition District spending, so a constitutional challenge to the rider has little precedent to rely on.
Why Initiative 71 survived
Initiative 71 took effect because District lawyers argued the initiative was "enacted" when voters approved it in November 2014, before the rider became law in December 2014. That timing argument is why possession and home cultivation remain legal, while commercial sales are not. Any new Council action that goes beyond the initiative's scope, such as licensing sellers or imposing a sales tax, is clearly barred.
Rescheduling and the "Schedule I" language
The rider is keyed to "schedule I" substances. If marijuana moves to Schedule III under 21 U.S.C. § 812, a textual argument emerges that the rider no longer applies to marijuana, since it is no longer a Schedule I substance. Appropriators can foreclose that argument by amending the rider language to name marijuana or cannabis directly. How the Senate drafts this fix is a key detail to watch. Even if marijuana is rescheduled, it would remain a federally controlled substance, and commercial sales outside the FDA drug-approval framework would stay illegal under federal law.
Drug testing under rescheduling
The Senate panel's push to keep federal drug testing intact connects to regulations such as the Department of Transportation's testing rules at 49 C.F.R. Part 40 and federal workplace testing guidelines administered by HHS. Those programs test for marijuana because it is a controlled substance. Appropriators want assurance that rescheduling does not weaken those testing obligations.
State-by-State and Regional Breakdown
The District is surrounded by jurisdictions that took very different paths, which sharpens the contrast between DC's constrained position and its neighbors' functioning markets.
| Jurisdiction | Status | Key details |
|---|---|---|
| District of Columbia | Possession and home grow legal; no retail sales | Initiative 71 effective Feb. 26, 2015; 2 oz. possession; 6 plants (3 mature); gifting market; separate licensed medical program |
| Maryland | Adult-use retail legal | Sales began July 1, 2023; regulated and taxed market adjacent to DC |
| Virginia | Possession and limited home grow legal; retail market not established | Legalization enacted 2021; creates similar unregulated supply problem to DC |
District of Columbia
Adults 21 and older may possess up to two ounces and cultivate six plants at home, but cannot purchase from licensed recreational retailers. Medical patients can buy from licensed dispensaries. Public consumption remains prohibited, and federal land within the District, which is extensive, remains subject to federal law regardless of local policy.
Maryland
Maryland's regulated market shows the infrastructure DC cannot build. Maryland voters approved legalization in November 2022, and licensed sales began in July 2023. District residents can and do cross the border to purchase, which shifts potential tax revenue to Maryland.
Virginia
Virginia legalized possession and home cultivation in 2021 but did not create a retail framework in the same period, leaving it in a position similar to DC's: legal to have, awkward to buy. The two jurisdictions are often cited together as examples of half-finished legalization.
Market and Business Implications
The rider keeps DC's cannabis economy informal, which deters institutional capital, rewards small gifting operators, and hands cross-border revenue to Maryland.
MSO and institutional capital
Multi-state operators (MSOs) have largely stayed out of the DC recreational market because there is no licensing path and no legal retail channel to invest in. The medical program offers a narrow entry point through a limited number of licenses, but the recreational opportunity that investors most want remains closed. Capital that might have flowed into DC retail is flowing to Maryland and other open markets instead.
The gifting economy
Dozens of gifting businesses operate in the District, relying on the legal fiction that cannabis is a free gift accompanying a purchased item. These operators face legal uncertainty, inconsistent enforcement, and no access to banking or standard commercial services. They also cannot claim the tax treatment of licensed operators. Section 280E of the Internal Revenue Code, which denies ordinary business deductions to trafficking in Schedule I and II substances, would become less of a burden for licensed operators if marijuana moves to Schedule III, but gifting shops are not licensed and have unclear tax status entirely.
Wholesale pricing read
Without a licensed, tested supply chain, DC lacks a transparent wholesale price benchmark. Product moves through informal channels, often sourced from out-of-state or home-grown supply, so prices reflect risk and opacity rather than competitive wholesale dynamics. A licensed market would likely compress retail prices over time as supply formalizes, as happened in Maryland and other mature adult-use states. Treat any DC price comparison with caution because the data are inconsistent.
Tax revenue forgone
A taxed recreational market would produce excise and sales tax revenue that currently goes uncollected. Estimates vary with tax design and license count. The more reliable observation is directional: Maryland's launch gave District residents a legal, taxed alternative across the border, so every month of delay increases the share of potential revenue that accrues to another jurisdiction.
Rescheduling effects
Rescheduling to Schedule III would ease the 280E burden for licensed operators nationally and could shift appropriations drafting. For DC, it would not by itself authorize commercial sales, since the rider would still bar the Council unless the text is read narrowly. Operators planning for a future DC market should treat rescheduling and rider repeal as separate, independent events.
What Experts Say
Legal analysts and policy advocates broadly agree that the rider's reach after rescheduling is genuinely uncertain, while disagreeing on whether appropriators will close that gap.
Advocates at the Marijuana Policy Project and the Drug Policy Alliance have said that the rider is a home-rule violation that Congress should drop, and that rescheduling strengthens the argument by undermining the rationale for treating cannabis as uniquely dangerous. They point to the House's repeated omission of the rider as evidence that a majority position exists for repeal in at least one chamber.
Delegate Eleanor Holmes Norton's office has said that the District should be treated like a state on cannabis policy and that appropriators are using the rider to impose a minority viewpoint on a jurisdiction that voted overwhelmingly the other way.
On the other side, Representative Andy Harris has argued that Congress has a constitutional responsibility to oversee the District and that marijuana policy carries public-health risks that justify federal intervention. Supporters of the rider in the Senate have generally treated it as a routine, low-cost provision rather than a priority fight, which explains why it survives even when it lacks vocal champions.
Legal scholars who follow appropriations law have noted that riders keyed to a statutory schedule are vulnerable to textual challenge when the schedule changes, which is why many expect appropriators to revise the language to name marijuana explicitly if rescheduling is finalized. That prediction, rather than any certainty about outcome, is the working assumption among most observers.
The core tension, as most analysts frame it: Congress can keep the rider cheaply every year, but each year that Maryland's market operates next door makes the policy harder to defend on practical grounds.
What's Next
The rider's fate will be decided in the FY2027 appropriations endgame, where the Senate panel's position gives defenders the early advantage.
Calendar and decision points
- Senate FSGG markup and floor action: The panel's decision to retain the rider sets the Senate baseline; watch for any amendment attempt to strip it at committee or on the floor.
- House position: The House has previously omitted the rider; whether it does so again determines the shape of conference negotiations.
- Conference or omnibus negotiations: Historically the rider is restored here. Any deal that drops it would be a notable break from the decade-long pattern.
- Rescheduling finalization: The final DEA and HHS action on Schedule III, including ALJ proceedings and any litigation, determines whether the rider's "Schedule I" language needs updating.
- Continuing resolution risk: If Congress passes a stopgap, the existing rider carries forward automatically, a common path to renewal.
Scenarios
- Status quo (most likely): The Senate retains the rider, conference restores it if the House drops it, and DC remains unable to license sales for another fiscal year.
- Textual update: Appropriators revise the language to name marijuana directly, closing any post-rescheduling loophole while preserving the block.
- Partial relief: A negotiated compromise allows regulation or taxation while limiting other provisions. This has been floated before but has not gained traction.
- Repeal: A change in congressional control or a high-priority bargain strips the rider, allowing the Council to move a tax-and-regulate bill. The Council would still need to pass legislation, set up licensing, and stand up a regulator, a process that would take many months.
What operators and investors should do
Plan on the assumption that sales remain blocked through at least the next fiscal year. Track conference text, not just committee action, since the final bill is what counts. Monitor how rescheduling language is drafted, because a change from "schedule I" to explicit marijuana references would signal appropriators' intent to hold the line indefinitely.
Further Reading
- Marijuana Moment, coverage of the Senate panel action on DC sales and federal drug testing: Senate Panel Wants To Keep Blocking DC From Legal Marijuana Sales
- Controlled Substances Act, 21 U.S.C. § 812 (drug schedules): https://www.law.cornell.edu/uscode/text/21/812
- Antideficiency Act, 31 U.S.C. § 1341: https://www.law.cornell.edu/uscode/text/31/1341
- District of Columbia Home Rule Act: https://code.dccouncil.gov/us/dc/council/code/titles/1/chapters/2
- Council of the District of Columbia, legislative information system: https://lims.dccouncil.gov
- U.S. House Committee on Appropriations, Financial Services and General Government bills: https://appropriations.house.gov
- U.S. Senate Committee on Appropriations: https://www.appropriations.senate.gov
- DEA Diversion Control Division, scheduling actions: https://www.deadiversion.usdoj.gov
- Federal Register, marijuana rescheduling rulemaking: https://www.federalregister.gov
Frequently asked questions
What is the DC marijuana sales appropriations rider?
It is a policy provision attached to the annual federal spending bill covering the District of Columbia. It bars the district from spending any funds, local or federal, to enact a system to legalize, tax, and regulate recreational cannabis sales. It is often called the Harris rider after Rep. Andy Harris (R-MD), who first offered it in 2014.
Why can Congress block DC from regulating marijuana sales?
Under the U.S. Constitution, Congress holds exclusive legislative authority over the District of Columbia. The DC Home Rule Act of 1973 delegated local governance to the district but allows Congress to review and override local laws, including through appropriations language. States have no equivalent exposure to congressional control over their budgets.
Is marijuana legal in Washington, DC?
Partly. Voters approved Initiative 71 in 2014, making it legal for adults 21 and older to possess up to two ounces, grow up to six plants (three mature), and transfer small amounts without payment. Legal retail sales for adult use have not been established because of the rider. DC's medical marijuana program, created separately, does operate licensed dispensaries.
How does the rider affect DC's medical marijuana program?
The rider targets recreational sales regulation and does not shut down the medical program, which was authorized by earlier DC law and is overseen by the Alcoholic Beverage and Cannabis Administration. Licensed medical dispensaries continue serving registered patients, while the adult-use market remains outside the regulated system.
What is the DC marijuana gifting market?
Because sales cannot be regulated, a gray market developed in which businesses sell a non-cannabis item, such as a sticker, art print, or juice, and 'gift' cannabis alongside it. Initiative 71 permits transferring up to one ounce without payment, and these businesses operate in that legal ambiguity. They are not licensed or taxed, and DC officials have periodically moved against some operators.
Why can't DC tax and regulate cannabis like states do?
Taxing and regulating sales requires the district to appropriate funds for licensing, enforcement, and administration. The rider prohibits spending on exactly that. DC lawmakers have said a regulated market would generate tax revenue, create licensed business opportunities, and bring quality and safety standards, none of which are possible while the rider stays in place.
Who supports and opposes keeping the rider?
Supporters, led historically by Rep. Andy Harris, argue Congress should not facilitate commercial cannabis markets while it remains federally illegal. Opponents include DC's elected officials, who cite home rule and local voter intent, and many Democrats and cannabis reform advocates who argue the district should govern its own affairs.
What is the latest congressional action on the rider?
As reported by Marijuana Moment in November 2026, a Senate appropriations panel's spending legislation would again keep the restriction blocking DC from legalizing commercial marijuana sales. The same coverage noted the panel also encouraged federal agencies to continue cannabis-related drug testing in connection with rescheduling. Final outcomes depend on the full appropriations process.
Has the rider ever been removed?
The rider has been included in enacted spending legislation every year since its introduction in 2014. While some House and Senate drafts and amendments have attempted to drop it, final appropriations packages have retained the language, so DC still cannot create a regulated adult-use retail market.
Could rescheduling cannabis change the rider's impact?
Rescheduling under the Controlled Substances Act would change federal drug classification but would not automatically remove the rider. The restriction is appropriations language that Congress must choose to omit. DC would still need Congress to drop or alter the provision before it could legally fund a regulated sales system.
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.